Vor Biopharma Inc. (VOR)
NASDAQ: VORHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VOR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.18B
- P/E (TTM)
- 0.06
- EPS (TTM)
- $300.56
- Dividend yield
- None
- 52-week range
- 7.21 – 26.00
- Day range
- 17.99 – 19.91
- Volume / Avg
- 1.55M / 945.67K
- Beta
- —
- Shares outstanding
- 61.43M
52-week range
VOR stock today
On Nov 20, VOR ended the session at $19.19, adding $0.67 (3.62%), versus the S&P 500's 3.70% decline. Shares are 26.2% below their 52-week high of $26.00, set on Sep 8, 2026 and 166.2% above the 52-week low of $7.21, in the middle of the past year's range. VOR is up 46.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 157.6%.
Vor Biopharma trades at 0.1x its trailing twelve-month earnings per share of $300.56.
Summary generated from market data by MetaCap's automated system. Methodology
About Vor Biopharma
Company profileVor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Jean-Paul Kress M.D.
- Headquarters
- Boston, MA
- Employees
- 76
- IPO year
- 2021
- Website
- vorbio.com
Financial highlights
Full financialsVor Biopharma reported a net loss of $696.0 million, compared with a loss of $116.9 million a year earlier. Diluted earnings per share came in at -$70.50.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-695.98M | $-116.91M | $-117.86M | $-92.09M | $-68.90M |
| EPS (diluted) | $-70.50 | $-34.03 | $-1.75 | $-2.33 | $-2.10 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$39.00+103.23%
- Strong buy 1
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-1.45 vs $-0.81
- Surprise
- -79.01%
VOR news
All VOR news- Vor Biopharma Inc. Expands RemeGen License to Add RC298 for $10 million UpfrontNasdaqVOR, LEN.B
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Vor Biopharma reports Q3 resultsSeeking Alpha
- Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA NephropathyGlobeNewswire
- William Blair Initiates Coverage of Vor Biopharma at OutperformNasdaq
- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.NasdaqPTGX, JNJ, LAB, XNCR
Vor Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TSHATaysha Gene Therapies Inc. | 3.72 | -1.33% | $1.21B | vs VOR |
| NVAXNovavax Inc. | 7.47 | -3.24% | $1.23B | vs VOR |
| INBXInhibrx Biosciences Inc. | 68.97 | -7.21% | $1.02B | vs VOR |
| IMCRImmunocore Holdings plc ADR | 26.41 | -0.83% | $1.36B | vs VOR |
| MESOMesoblast Limited ADR | 10.89 | -2.59% | $1.41B | vs VOR |
| WWBWindward Bio Group AG | 24.29 | +1.15% | $1.45B | vs VOR |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs VOR |
| IMTXImmatics N.V. | 5.77 | -3.03% | $878.58M | vs VOR |
Indexes, lists and sector
Vor Biopharma stock FAQ
What is Vor Biopharma's stock price today?
VOR last traded at $19.19 as of Nov 20, 4:00 PM EST, up 3.62% on the day. Prices are delayed at least 15 minutes.
Does Vor Biopharma pay a dividend?
No. Vor Biopharma does not currently pay a regular cash dividend.
What is VOR's P/E ratio?
VOR trades at a trailing P/E ratio of 0.06.
Who is Vor Biopharma's CEO?
Dr. Jean-Paul Kress M.D. is the chief executive officer of Vor Biopharma Inc., which has about 76 employees.
Has VOR ever split its stock?
Yes. The most recent VOR stock split was a 1-for-20 split on Sep 19, 2025.
What is the VOR 52-week high?
The 52-week high for VOR is $26.00 and the 52-week low is $7.21. The stock is currently 26.2% below its high.